Pharma MarFRA:PMRA -1.80%83 Net Margin % is 3.57% as of Mar. 2026, which is 54% below its 10-year median of 7.83. GuruFocus rates FRA:PMRA with a GF Score™ of 83/100 and a GF Value™ of €83.37 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, Pharma Mar ranks better than 90.81% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Pharma Mar's Net Income for the
three
months ended in Mar. 2026 was €1.5 Mil. Pharma Mar's Revenue for the
three
months ended in Mar. 2026 was €42.9 Mil. Therefore, Pharma Mar's net margin for the quarter that ended in Mar. 2026 was 3.57%.
The historical rank and industry rank for Pharma Mar's Net Margin % or its related term are showing as below:
FRA:PMRA'
s Net Margin % Range Over the Past 10 Years
Min: -16.84 Med: 7.83 Max: 50.85
Current: 29.01
FRA:PMRA's Net Margin % is ranked better than 90.81% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs FRA:PMRA: 29.01
Pharma Mar (FRA:PMRA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pharma Mar Net Margin % Related Terms
Pharma Mar Net Margin % Historical Data
* Premium members only.
The historical data trend for Pharma Mar's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PMRA vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Pharma Mar's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (FRA:PMRA) has a Net Margin % of 3.57% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pharma Mar and its competitors. This is 54% below median its historical median of 7.83. According to the industry distribution chart, Pharma Mar ranks #87 out of 947 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Pharma Mar's Net Margin % too high?
Pharma Mar's current Net Margin % of 3.57% is 54% below median its 10-year median of 7.83. Based on the distribution chart, Pharma Mar ranks #87 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #87 out of 947 companies for Net Margin %. This places Pharma Mar in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pharma Mar and its competitors. Pharma Mar's current Net Margin % is 3.57%, which is 54% below median its own 10-year median of 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.05 — trading 18.4% below its estimated fair value. The current Net Margin % is 3.57%, which is 54% below median its 10-year median of 7.83. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current Net Margin % is 3.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (FRA:PMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €68.05 is trading 18.4% below its estimated GF Value™ of €83.37.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for FRA:PMRA:
Net Margin %: 3.57% (54% below median its 10-year median of 7.83)
GF Value™: €83.37 vs. price of €68.05 (18.4% below fair value)
No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score
Get the complete analysis for FRA:PMRA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PMRA has been successfully added to your 
